Company news

PDS Biotechnology Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023

July 24, 2023

PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023

July 16, 2023

PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301

July 10, 2023

PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 29, 2023

PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

June 19, 2023

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer

June 13, 2023

PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET

June 4, 2023

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients

May 24, 2023

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

May 17, 2023

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results

May 14, 2023

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results

May 3, 2023

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients

April 26, 2023

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program

April 23, 2023

PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023

April 11, 2023

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023

April 2, 2023

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023

March 29, 2023

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results

March 27, 2023

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results

March 15, 2023

PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal

February 28, 2023

PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor

February 26, 2023

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™

February 15, 2023

PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses

February 7, 2023

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress

February 5, 2023

PDS Biotech Announces Participation in the Channelchek Takeaway Series

January 25, 2023

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

January 2, 2023

PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months

December 27, 2022

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer

December 14, 2022

PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update

November 13, 2022

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

November 13, 2022

PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022)

November 6, 2022

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results

October 30, 2022

PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy

October 16, 2022

PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022

October 11, 2022

PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers

October 10, 2022

PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 6, 2022

PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022

October 4, 2022

PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®

October 2, 2022

PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 22, 2022

PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers

September 20, 2022

PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance

August 23, 2022

PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update

August 7, 2022

PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications

August 3, 2022

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2022 Financial Results

July 25, 2022

PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting

July 13, 2022

PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel

June 2, 2022

PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101

June 1, 2022

PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe

May 30, 2022

PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022

May 25, 2022

PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022

May 25, 2022

PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Development

May 17, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 75 decks. Every deck is listed under its year.